With this acquisition, Clinipace has expanded its regulatory and strategic development expertise and increased its staff by 20%. The Regulus team will remain in Colorado with the same management structure and personnel and will operate as the regulatory affairs, strategic development and quality assurance consultancy division of Clinipace.
Brenda Fielding, Regulus president, will become executive vice president of regulatory affairs for Clinipace. Prior to Regulus, she held senior management positions in U.S. pharmaceutical and biotechnology companies, involved in clinical development over a range of therapeutic areas including oncology, anti-infectives, immunotherapeutics and ophthalmology.
With specific expertise in oncology, among other therapeutic areas, Clinipace has managed over 200 contract research and regulatory projects. Headquartered in Research Triangle Park, N.C., it also has operations in Overland Park, Kan., Boulder, Colo., and South American operations in Brazil, Argentina and Peru.
